Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium

We recently published 10 Stocks With 10-60% Upside. Merus NV (NASDAQ:MRUS) is one of the top performers on Monday.

Shares of Merus NV soared to a new record high on Monday, as investors gobbled up shares following news that it was set to be acquired by Genmab AS at a 41-percent premium.

In a statement, Genmab AS said that it entered into an agreement with Merus NV (NASDAQ:MRUS) for the acquisition of the latter, through its subsidiary, Purchaser, for $8 billion.

Under the deal, Purchaser will acquire all of Merus NV’s (NASDAQ:MRUS) outstanding shares at a price of $97 apiece.

The tender offer is subject to the satisfaction of customary closing conditions, including a minimum acceptance condition of at least 80 percent of Merus NV’s (NASDAQ:MRUS) common shares.

The companies said the purchase price stands at a 41-percent premium over Merus NV’s (NASDAQ:MRUS) $68.89 closing price on September 26, and approximately 44 percent over its 30-day volume-weighted average price of $67.42.

Genmab said it will finance the transaction through a combination of cash on hand and approximately $5.5 billion of non-convertible debt financing. Genmab has obtained a funding commitment from Morgan Stanley Senior Funding, Inc. for the said amount.

While we acknowledge the potential of MRUS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.